Tela Bio, Inc. · NASDAQ:TELA
Tela Bio — Investor Presentation (May 2022)
16 slides from Tela Bio's investor presentation, May 10, 2022
Slide 1: A Soft-Tissue Preservation and Restoration Company
A Soft - Tissue Preservation and Restoration Company Investor Presentation May 2022
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All statements other than statements of historical facts contained in this document, including but not limited to statements regarding possi
Slide 3: Redefining soft tissue reconstruction with a differentiated category of tissue reinforcement materials
Redefining soft tissue reconstruction with a differentiated category of tissue reinforcement materials ~$2B U.S Market Opportunity 1 in hernia repair , abdominal wall reconstruction and plastic and reconstructive surgery 3 Innovative Products Compelling Clinical Evidence Products Offer Attractive Va
Slide 4: Creating Advanced Biologic Materials
Creating Advanced Biologic Materials Purposefully designed to address shortcomings & unmet clinical needs
Slide 5: OviTex: ~$1.5 Billion Annual U.S. Hernia Market Opportunity
OviTex : ~$1.5 Billion Annual U.S. Hernia Market Opportunity
Slide 6: Ventral Hernia Patients Range in Complexity
Ventral Hernia Patients Range in Complexity
Slide 7: Current Ventral Hernia Treatment Options: No Perfect Product
Current Ventral Hernia Treatment Options: No Perfect Product
Slide 8: Growing Need for Alternative to Permanent Synthetic Mesh
Growing Need for Alternative to Permanent Synthetic Mesh 1 Hernia and Abdominal Surgeries Survey (Oct 2020). 2 www.drugwatch.com (October 2020)
Slide 9: OviTex Reinforced Tissue Matrix: a More Natural Hernia Repair
OviTex Reinforced Tissue Matrix: a More Natural Hernia Repair 䉼
Slide 10: OviTex LPR for Laparoscopic & Robotic Hernia Repair
OviTex LPR for Laparoscopic & Robotic Hernia Repair
Slide 11: Compelling Clinical Evidence
Compelling Clinical Evidence
Slide 12: OviTex PRS: ~$600 Million Annual U.S. Plastic & Reconstructive Surgery Market Opportunity
OviTex PRS: ~$600 Million Annual U.S. Plastic & Reconstructive Surgery Market Opportunity 1 Management estimate. Market size based on sales of current biologics
Slide 13: OviTex PRS: Purposely Designed for Plastic and Reconstructive Surgery
OviTex PRS: Purposely Designed for Plastic and Reconstructive Surgery
Slide 14: Growth Strategy
Growth Strategy MARKET EXPANSION © Launch new product features and designs for OviTex and OviTex PRS ° Initiate robotic hernia post-market study COMMERCIAL EXECUTION Scale direct sales force INCREASE ADOPTION Drive account manager productivity Promote broader awareness of OviTex & OviTex PRS product
Slide 15: Delivering Revenue Growth
Delivering Revenue Growth Annual Revenue Revenue CAGR: 62% $18.2 $154 $83 $43 | 2017-2018 = 2019-2020 ($ millions) $295 2021 First Quarter Revenue Revenue Growth: 40% $8.2 $5.9 aa:21 01:22 ($ millions) Q1 2022 Performance | Revenue growth of 40% year over year | Cash and Cash equivalents (as of Marc
Slide 16: Investment Highlights
Investment Highlights Advanced reinforced tissue matrix portfolio supported by compelling clinical evidence Focused on ~$2.0 billion annual U.S. total addressable markets Driving commercial adoption with targeted direct-sales approach Recent product launches in growing markets: robotic hernia surger